Valion Bio sells Series C preferred shares, warrants in $4.72 million private placement
VBIO•Valion Bio agreed to privately place 4,717 Series C non-voting convertible preferred shares for $4.72 million, including $1.5 million in cash and $3.22 million retained to satisfy overdue cash true-up payments. Purchasers also receive warrants for 2,524,343 common shares at an initial exercise price of $1.0092 per share.
1. Series C placement
Valion Bio agreed on October 26, 2026, to privately place 4,717 Series C non-voting convertible preferred shares for $4.72 million. The purchase price comprises $1.5 million in cash and $3.22 million retained by purchasers to satisfy overdue cash true-up payments. Purchasers also receive warrants to buy 2,524,343 common shares at an initial exercise price of $1.0092 per share.
2. Separate Series B deal
In a separate private placement to 3i, Valion Bio is selling 50 Series B non-voting convertible preferred shares for $50,000. The placement includes warrants to purchase 1,539 common shares at an initial exercise price of $1.0092 per share.
